| Clinically isolated syndrome
Briumvi vs Copaxone
Side-by-side clinical, coverage, and cost comparison for clinically isolated syndrome.Deep comparison between: Briumvi vs Copaxone with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCopaxone has a higher rate of injection site reactions vs Briumvi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Copaxone but not Briumvi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Briumvi
Copaxone
At A Glance
IV infusion
Every 24 weeks
Anti-CD20 monoclonal antibody
SC injection
Daily or 3x weekly
Immunomodulator
Indications
- Multiple Sclerosis, Relapsing-Remitting
- Clinically isolated syndrome
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Multiple Sclerosis, Relapsing-Remitting; Clinically isolated syndrome; Multiple Sclerosis, Secondary Progressive 150 mg IV infusion (first infusion), followed by 450 mg IV infusion 2 weeks later, then 450 mg IV every 24 weeks; pre-medicate with methylprednisolone (or equivalent corticosteroid) and antihistamine before each infusion.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive 20 mg/mL SC once daily OR 40 mg/mL SC three times per week (at least 48 hours apart); the two strengths are not interchangeable.
Contraindications
- Active HBV infection
- History of life-threatening infusion reaction to ublituximab-xiiy
- Known hypersensitivity to glatiramer acetate or mannitol, including anaphylaxis
Adverse Reactions
Most common (>=10%) Infusion reactions, upper respiratory tract infections
Serious Infusion reactions, infections, reduction in immunoglobulins, liver injury
Postmarketing Liver injury, progressive multifocal leukoencephalopathy
Most common (>=2%) Injection site erythema, pain, pruritus, mass, edema, and inflammation; vasodilatation, rash, dyspnea, chest pain, nausea, palpitations, lymphadenopathy, asthenia, anxiety, infection
Serious Anaphylactic reactions, immediate post-injection reaction, chest pain, lipoatrophy and skin necrosis, potential effects on immune response, hepatic injury
Postmarketing Sepsis, SLE syndrome, thrombosis, myocardial infarct, thrombocytopenia, lymphoma-like reaction, acute leukemia, cirrhosis, hepatic injury, anaphylactic reactions, cerebrovascular accident, pulmonary embolus, blindness
Pharmacology
Anti-CD20 chimeric monoclonal IgG1 antibody with reduced fucose content; binds CD20 on pre-B and mature B lymphocytes and causes cell lysis via antibody-dependent cellular cytolysis and complement-dependent cytolysis.
Glatiramer acetate is an immunomodulator thought to act by modifying immune processes responsible for MS pathogenesis; upon SC administration, glatiramer acetate-specific suppressor T-cells are induced and activated in the periphery.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Briumvi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Copaxone
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (1/12) · Qty limit (11/12)
UnitedHealthcare
Briumvi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Copaxone
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Briumvi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Copaxone
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BriumviView full Briumvi profile
CopaxoneView full Copaxone profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.